AzTrials
AzTrials

Chronic Kidney DiseaseCkd-WEEDNCT07729683

Evaluation of the Effect of a Daily Dose of Wakame Seaweed on Reducing Circulating Concentrations of Advanced Glycation End Products in Patients With Stage III Chronic Kidney Disease

A study testing Consumption of wakame in people with Chronic Kidney Disease, run by Groupe Hospitalier de la Rochelle Ré Aunis at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Persistent glomerular hyperfiltration is a characteristic feature of the early stages of kidney disease and represents a factor in the progression of chronic kidney disease (CKD). Read more about this study

Who is it for?
Ages 18 to 90 years
Conditions the study is for
Chronic Kidney Disease
What is being tested?
Consumption of wakame
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteFrance
Study dates
27 Jan 2026to Oct 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients not under legal protection
  • Patients aged ≥ 18 and < 90 years
  • Patients with stage IIIA-B chronic kidney disease (CKD) (estimated GFR by CKD-EPI ≥ 30 mL/min and < 60 mL/min)
  • Patients receiving optimized nephroprotective treatment (ACE inhibitors, SGLT2 inhibitors)
  • Patients who have signed the informed consent form
  • Patients not participating in another clinical study
  • Patients affiliated with or benefiting from a social security scheme

Who cannot join

  • Adult patients under legal protection
  • Patients under 18 years old or over 90 years old
  • Patients with uncontrolled thyroid disorders
  • Patients with decompensated heart failure
  • Patients consuming other dietary supplements containing seaweed or iodine (e.g., multivitamins)
  • Pregnant or breastfeeding women
  • Patients with acute kidney injury
  • Patients who decline to participate in the study

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • Groupe Hospitalier de La Rochelle Ré Aunis

    La Rochelle, 17000

    Recruiting

Other trials in France

About this study

Official title: Evaluation of the Effect of a Daily Dose of Wakame (Undaria Pinnatifida) on Reducing Circulating Concentrations of Advanced Glycation End Products (AGEs: Methylglyoxal) in Patients With Stage III Chronic Kidney Disease

Persistent glomerular hyperfiltration is a characteristic feature of the early stages of kidney disease and represents a factor in the progression of chronic kidney disease (CKD). In this context, the benefit of low-protein diets (less than 0.8g/kg/day) has been demonstrated in slowing the progression of CKD, although the underlying pathophysiological mechanisms remain unclear.

Some studies suggest that the effects of protein on renal hemodynamics are primarily linked to the quality of the protein, particularly the amount of AGEs (Advanced Glycation End Products) consumed.

Read more

Recently, edible seaweeds have gained popularity in Western countries due to their anti-inflammatory, anti-diabetic, and antihypertensive properties. These seaweeds are also associated with the above-average longevity of certain Asian populations who consume them daily. Wakame seaweed (Undaria pinnatifida), which is locally harvested along the French Atlantic coast, has shown promising biological properties, notably antihypertensive and anti-diabetic effects. It has also been recently demonstrated that fucoxanthin, a compound found in high concentrations in wakame, possesses strong anti-AGE activity.

Dietary modifications are essential for nephroprotection, but they are often difficult to implement. This highlights the need to develop approaches that are both acceptable on a daily basis and sustainable in the long term for patients.

A Michelin-starred chef, known for regularly incorporating seaweed into his cuisine, is a sponsor of the project and has validated a set of adapted recipes that will be offered to participants to accompany the daily wakame supplementation.

The investigator's hypothesis is that a daily dose (5 grams of French wakame, dehydrated at low temperature and in flake form), equivalent to the average daily intake in Japan, could reduce circulating AGE levels in patients with stage III CKD. This would provide an additional protective effect when combined with the standard low-protein diet, helping to slow the progression of CKD over the long term.

Read the detailed description

Persistent glomerular hyperfiltration is a characteristic feature of the early stages of chronic kidney disease (CKD), particularly observed in the initial phases of diabetic nephropathy, and constitutes a major factor in the progression of kidney failure. In this context, the benefit of low-protein diets (less than 0.8g/kg/day) in slowing CKD progression has been demonstrated, though the underlying pathophysiological explanation remains unclear.

Among the proposed mechanisms, a study demonstrated that an oral protein load (cooked red meat) led to a significant 26% increase in glomerular filtration rate, measured by inulin clearance, in healthy subjects 90 minutes after ingestion. This protein-induced glomerular hyperfiltration is used to assess renal functional reserve, defined as the kidney's ability to increase renal blood flow and GFR after a protein load, via modulation of intrarenal hemodynamics.

The precise mechanisms underlying these hemodynamic and functional changes remain controversial. A study suggested that the renal hemodynamic effects of a protein load are primarily related to the amount of Advanced Glycation End Products (AGEs) ingested. Indeed, the experimental models used to study renal functional reserve (e.g., amino acid perfusions, red meat meals) also involved significant AGE exposure.

AGEs are formed through non-enzymatic glycation reactions, where sugars bind to peptides or nucleic acids, leading to cellular aging via increased ROS (Reactive Oxygen Species) production and activation of inflammatory pathways. Methylglyoxal (MG) and Carboxymethyl-lysine (CML), two major circulating and tissue AGEs, are predominantly cleared by the kidneys and accumulate with age.

While it was previously thought that AGEs were primarily endogenously produced, it is now well established that dietary intake is a significant source, especially via harmful cooking methods (high-temperature cooking with oil and little water), both in healthy individuals and those with CKD. An oral AGE load has been shown to significantly increase circulating CML levels within 90 minutes.

In a pilot human study, it has been demonstrated that an oral protein load rich in AGEs led to greater mobilization of renal functional reserve (increased renal blood flow and renal oxidative metabolism) compared to an iso-protein, low-AGE load. This finding supports a key role for AGE content and protein quality, beyond quantity alone, in the nephroprotective effects of low-protein diets.

In animal models, aged mice fed an AGE-rich diet developed chronic kidney disease with glomerular and tubular damage. In humans, dietary AGE intake contributes to inter-individual variation in CKD progression. Reducing dietary AGE intake has been shown to decrease plasma and peritoneal dialysis AGE levels in non-diabetic dialysis patients. Additionally, two months of treatment with sevelamer, a phosphate binder, in patients with diabetic nephropathy (stages II to IV) led to a significant reduction in MG and CML, HbA1c, and markers of inflammation and oxidative stress, while increasing levels of the AGE receptor AGER1. However, this approach involves adding another medication to patients already under high therapeutic pressure, with associated risks of poor adherence.

Seaweed consumption is an ancestral practice in Asia, where life expectancy is generally higher than in Western countries. Regular seaweed consumption may partly explain this longevity. Brown seaweeds are exceptionally rich in fiber, phlorotannins, carotenoids, trace elements (copper, chromium, zinc, selenium, manganese, iron), and vitamins (C, B1, B2, B6, B12). Recent studies have shown that the seaweed Ishige okamurae, native to Okinawa, exhibits anti-AGE properties. The phlorotannin diphlorethohydroxycarmalol (DPHC) from Ishige okamurae has been shown to prevent diabetic nephropathy in mouse mesangial cells by inhibiting AGE-RAGE interactions.

The seaweed Undaria pinnatifida (Up), commonly known as wakame in Japan, has been present along the French Atlantic coast since the 1970s, having been introduced from Asia. Low-temperature dehydration (40°C), in line with traditional Asian methods, helps preserve its biological properties.

Wakame has demonstrated various biological activities, including ACE (angiotensin-converting enzyme) inhibition. A daily intake of 5g over 8 weeks resulted in a 10 mmHg reduction in blood pressure in both Japanese and non-Japanese hypertensive individuals. Wakame also improves postprandial glycemic control in both humans and rats via PPAR activation and improved GLUT4 membrane translocation in myocytes. Fucoxanthin, found in high concentrations in wakame, has recently been shown to possess potent anti-AGE activity.

Wakame also has a pleasant umami and iodine-rich taste with a texture appreciated by chefs, making it a more appealing option for daily use among patients already facing heavy therapeutic burdens.

Dietary changes are essential in nephroprotection, but they are difficult to implement, underlining the importance of developing strategies that are practical, acceptable, and sustainable for patients.

A Michelin-starred chef, known for his regular use of seaweed in cuisine, is the project sponsor and has validated a set of tailored recipes that will be provided to participants to accompany daily wakame supplementation. Some of these recipes are presented in the appendix of the protocol.

To investigator's knowledge, no study has yet evaluated the impact of daily wakame intake on the reduction of circulating AGE concentrations or on nephroprotection.

Thje investigator's hypothesis is that a daily dose of 5g of wakame (equivalent to the average daily intake in Japan) could reduce circulating AGE concentrations (specifically methylglyoxal). Lowering AGE levels beyond that achieved by protein restriction alone could offer additional protection against CKD progression.

Being tested
Consumption of wakame
Keywords
Advanced Glycation End Products, AGEs, Chronic kidney disease (CKD), Wakame seaweed
Medical subject headings
Renal Insufficiency, Chronic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Consumption of wakameDietary supplement

    Consumption of 5g/day of wakame during one of the three meals of the day during three months.

Study groups in NCT07729683
Study groupRoleWhat they receive
Experimental groupExperimentalConsumption of 5g/day of wakame (Undoria pinnatifida) during one of the three meals of the day for a period of three months.
Receives: Dietary Supplement: Consumption of wakame

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Circulating AGE

    Circulating AGE measurement by plasma methylglyoxal (MG) measurement at M3

    Measured: From enrollment to the end of 3 months follow-up

Secondary outcomes (6)
  1. Proteinuria

    Proteinuria measurement (in g/g creatinine in urine) at M3

    Measured: From enrollment to the end of 3 months follow-up

  2. Ambulatory blood pressure

    Ambulatory blood pressure (systolic and diastolic blood pressure) monitoring (ABPM) over 24 hours at M3

    Measured: From enrollment to the end of 3 months follow-up

  3. Plasma creatinine clearance

    Calculation of estimated plasma creatinine clearance (CKD-epi) at M3

    Measured: From enrollment to the end of 3 months follow-up

  4. HbA1c

    HbA1c measurement at M3

    Measured: From enrollment to the end of 3 months follow-up

  5. Lipid profile

    Lipid profile (TG, LDLc, and HDLc) measurement at M3

    Measured: From enrollment to the end of 3 months follow-up

  6. TSH

    TSH measurement at M3

    Measured: From enrollment to the end of 3 months follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jul 2026
  2. Study start27 Jan 2026
  3. Primary completionOct 2027 (estimated)
  4. Study completionOct 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07729683
Sponsor's protocol ID
P02040
Acronym
Ckd-WEED
Status last verified
Jul 2026
First submitted
16 Sep 2025
Last updated
27 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be made available with publication. A Digital Object Identifier will be used and Data will be available at www.recherche.data.gouv.fr

Questions about this trial

What is this clinical trial studying?

A study testing Consumption of wakame in people with Chronic Kidney Disease, run by Groupe Hospitalier de la Rochelle Ré Aunis at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Cécile Duchiron (+335 46 68 45 67, cecile.duchiron@ght-atlantique17.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Circulating AGE (time frame: From enrollment to the end of 3 months follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in